Exploring ‘Junk DNA’ to find undiscovered causes of cancer
Using a new way to measure genetic variation in key sections of noncoding DNA.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Using a new way to measure genetic variation in key sections of noncoding DNA.
Finding which MEK inhibitors work best for children with acute myeloid leukaemia.
Stopping protein activity to stop anaplastic large cell lymphomas from growing.
Looking at molecular makeup and MRIs to characterise infant ependymoma.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Finding drugs which target genes that drive high-risk acute lymphoblastic leukaemia.
Looking at the genetics of bone marrow samples to see which genes affect resistance to treatment.
Assessing whether blocking a protein's activity could improve survival and reduce side effects.